// App-Quantinova.ai

P2-11-02 : Breast Cancer Index predicts benefit from extended endocrine therapy in HR+ breast cancer

Researchers

Presenter

  • John Bartlett

Principal Investigators

  • Dennis Sgori

  • Kai Treuner

  • Yi Zhang

  • Tammy Piper

  • Ranelle Shalunga

  • Ikhlaaq Ahmed

  • Lucy Doos

  • Sarah Thornber

  • Elena Brachtel

  • Sarah Pirrie

  • Catherine Schnabel

  • Daniel Rea

Medical Centers

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • Massachusetts General Hospital, Boston, MA

  • Biotheranostics Inc., San Diego, USA

  • University of Birmingham, Cancer Research UK Clinical Trials Unit (CRCTU), Birmingham, United Kingdom

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Homeobox B13

Drug/Treatment

  • Tamoxifen

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved